<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566017</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F60</org_study_id>
    <nct_id>NCT03566017</nct_id>
  </id_info>
  <brief_title>Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease</brief_title>
  <official_title>Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of PB-102-F60 is to evaluate the long-term safety, tolerability, and efficacy
      parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in
      adult Fabry patients who have successfully completed studies PB-102-F20 or PB-102-F30.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of PB-102-F60 is to evaluate the long-term safety, tolerability, and efficacy
      parameters of 1 mg/kg pegunigalsidase alfa every other week in adult Fabry patients who have
      successfully completed studies PB-102-F20 or PB-102-F30. Patients will be enrolled to receive
      1 mg/kg pegunigalsidase alfa as intravenous infusions every 2 weeks (Â±3 days). The duration
      of treatment will be no less than 24 months and up to 48 months or until pegunigalsidase alfa
      is commercially available to the patient at the discretion of the Sponsor. An interim
      analysis may be performed for administrative purposes during the conduct of the study. For
      the analysis, available efficacy and safety parameters will be summarized using descriptive
      statistics.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label extension study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment-related adverse events</measure>
    <time_frame>Through study completion, 4 years</time_frame>
    <description>CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>Once a month for the first 12 months, then every 3 months until the end of the study, 4 years</time_frame>
    <description>Estimated glomerular filtration rate (eGFRCKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac assessment</measure>
    <time_frame>Every 12 months up to the end of the study, 4 years</time_frame>
    <description>Left Ventricular Mass Index (g/m2) by magnetic resonance imaging (MRI) and Echocardiograph, and exercise tolerance (Stress Test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers for Fabry disease</measure>
    <time_frame>Every 3 months the first 12 months and every 6 months up to the end of the study, 4 years</time_frame>
    <description>Plasma Gb3, plasma Lyso-Gb3, and urine Lyso-Gb3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of pain medication use</measure>
    <time_frame>Every two weeks for 4 years</time_frame>
    <description>Frequency of pain medication use, or pre-infusion medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>Every 3 months the first 12 months and every 6 months up to the end of the study, 4 years</time_frame>
    <description>Protein/Creatinine ratio, spot urine test (UPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>Every 6 months up to the end of the study, 4 years</time_frame>
    <description>short form Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom assessment</measure>
    <time_frame>Every 6 months up to the end of the study, 4 years</time_frame>
    <description>Mainz Severity Score Index (MSSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Every 6 months up to the end of the study, 4 years</time_frame>
    <description>quality of life (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Experimental open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegunigalsidase alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegunigalsidase alfa</intervention_name>
    <description>Recombinant human alpha galactosidase A</description>
    <arm_group_label>Experimental open label</arm_group_label>
    <other_name>PRX-102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of study PB-102-F20 or PB-102-F30

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method. Acceptable methods of contraception include hormonal products, intrauterine
             device, or male or female condoms. Contraception should be used for 1 month after
             treatment termination.

        Exclusion Criteria:

          -  Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with patient
             compliance with the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UAB Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Disease, Baylor Healthcare</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eccles Primary Children's Outpatient Services Building</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O+O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital Klinisk Forskningspost</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Slovenj Gradec</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>PRX-102</keyword>
  <keyword>pegunigalsidase alfa</keyword>
  <keyword>Fabry disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

